Targeted Immunostimulants; A Promising Approach to In Situ Immunisation

Time: 9:00 am
day: Day Two


  • Assess the role of immunogenic cell death in propogating more robust immune responses in patients on combination therapy with immunotherapeutics such as check-point inhibitors; a promising approach to increase durability of response
  • Review how targeted immunostimulators now look to generate innate immune responses to tumours while increasing systemic tolerability
  • Examine how homogeneous antibody drug conjugates optimised to deliver combinations of mechanistically different payloads demonstrate that targeted “in situ immunisation” is feasible